Primary progressive multiple sclerosis

9 trials 2 recruiting MedDRA PT
9 Registered trials
2 Recruiting
8 Unique sponsors
21 Unique IMPs
5 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 4
N Neurology/Psychiatry (ATC N) 2
H Endocrinology (ATC H) 1
R Respiratory (ATC R) 1
— ATC code not specified 5
A Gastroenterology (ATC A) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 10 substances
Monoclonal antibody (immune, humanized) 2 substances
BTK inhibitor 2 substances
Interferon 2 substances
Corticosteroid 1 substance
Analgesic / antipyretic 1 substance
CAR-T cell therapy 1 substance
Monoclonal antibody (human) 1 substance
Monoclonal antibody (chimeric) 1 substance
Phase III: 5 Phase II: 1 Phase I/II: 1 Phase I: 1 Phase I (First in Human): 1

Filter these 9 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 9 trials

Phase III

5 trials
  • F. Hoffmann-La Roche AG Commercial
    DIPHENHYDRAMINE HYDROCHLORIDE; OCRELIZUMAB
    2023-505980-36-00 9 countries 2019 n=363
    Ended
  • F. Hoffmann-La Roche AG Commercial
    DIPHENHYDRAMINE HYDROCHLORIDE; METHYLPREDNISOLONE; OCRELIZUMAB; PARACETAMOL
    2023-506515-18-00 11 countries 2020 n=310
    Ended
  • Genzyme Corp. Commercial
    TOLEBRUTINIB
    2024-514495-41-00 19 countries 2020 n=487
    Ended
  • Zenas Biopharma (USA) LLC Commercial
    ORELABRUTINIB
    2025-524316-11-00 20 countries n=398
    Pending
  • Rigshospitalet Academic
    OCRELIZUMAB; RITUXIMAB
    2024-514287-84-00 1 country 2021 n=600
    Ended

Phase II

1 trial
  • Antwerp University Hospital Academic
    DIMETHYL FUMARATE; FINGOLIMOD; GLATIRAMER ACETATE; INTERFERON BETA-1A; METFORMIN HYDROCHLORIDE; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; OZANIMOD; PEGINTERFERON BETA-1A; PONESIMOD; RECOMBINANT INTERFERON BETA-1B; SIPONIMOD; TERIFLUNOMIDE
    2023-503190-38-00 1 country 2023 n=120
    Ended

Phase I/II

1 trial
  • Novartis Pharma AG Commercial
    RAPCABTAGENE AUTOLEUCEL
    2024-514006-31-00 4 countries 2026 n=18
    Recruiting

Phase I

1 trial
  • Centre Hospitalier Universitaire De Nantes Academic
    IMP not specified
    2023-509538-20-01 1 country 2025 n=15
    Recruiting

Phase I (First in Human)

1 trial
  • Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla Academic
    IMP not specified
    2023-508457-10-00 1 country 2024 n=50
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
F. Hoffmann-La Roche AG Commercial 2 Phase III 0
Genzyme Corp. Commercial 1 Phase III 0
Zenas Biopharma (USA) LLC Commercial 1 Phase III 0
Novartis Pharma AG Commercial 1 Phase I/II 1
Centre Hospitalier Universitaire De Nantes Academic 1 Phase I 1
Antwerp University Hospital Academic 1 Phase II 0
Rigshospitalet Academic 1 Phase III 0
Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla Academic 1 Phase I (First in Human) 0
New trials by year
2019
1
2020
2
2021
1
2023
1
2024
1
2025
1
2026
1
← All indication landscapes